-
Je něco špatně v tomto záznamu ?
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1)
M. Santoni, F. Massari, ZW. Myint, R. Iacovelli, M. Pichler, U. Basso, J. Kopecky, J. Kucharz, S. Buti, A. Salfi, T. Büttner, U. De Giorgi, R. Kanesvaran, O. Fiala, E. Grande, PA. Zucali, G. Fornarini, MT. Bourlon, S. Scagliarini, J....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
- MeSH
- index tělesné hmotnosti MeSH
- inhibitory proteinkinas terapeutické užití MeSH
- karcinom z renálních buněk * patologie MeSH
- lidé MeSH
- nádory ledvin * patologie MeSH
- prognóza MeSH
- retrospektivní studie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Obesity has been associated with improved response to immunotherapy in cancer patients. We investigated the role of body mass index (BMI) in patients from the ARON-1 study (NCT05287464) treated by dual immuno-oncology agents (IO+IO) or a combination of immuno-oncology drug and a tyrosine kinase inhibitors (TKI) as first-line therapy for metastatic renal cell carcinoma (mRCC). PATIENTS AND METHODS: Medical records of patients with documented mRCC treated by immuno-oncology combinations were reviewed at 47 institutions from 16 countries. Patients were assessed for overall survival (OS), progression-free survival (OS), and overall clinical benefit (OCB), defined as the sum of the rate of partial/complete responses and stable disease. Univariate and multivariate analyses were used to explore the association of variables of interest with survival. RESULTS: A total of 675 patients were included; BMI was >25 kg/m2 in 345 patients (51%) and was associated with improved OS (55.7 vs. 28.4 months, P < .001). The OCB of patients with BMI >25 kg/m2 versus those with BMI ≤25 kg/m2 was significantly higher only in patients with nonclear cell histology (81% vs. 65%, P = .011), and patients with liver metastases (76% vs. 58%, P = .007), Neutrophil to lymphocyte ratio >4 (77% vs 62%, P = .022) or treated by nivolumab plus ipilimumab (77% vs. 64%, P = .044). In the BMI ≤25 kg/m2 subgroup, significant differences were found between patients with NLR >4 versus ≤4 (62% vs. 82%, P = .002) and patients treated by IO+IO versus IO+TKIs combinations (64% vs. 83%, P = .002). CONCLUSION: Our study suggests that the prognostic significance and the association of BMI with treatment outcome varies across clinico-pathological mRCC subgroups.
Chair of Oncology Interdisciplinary Department of Medicine University of Bari Aldo Moro Bari Italy
Department of Biomedical Sciences Humanitas University Pieve Emanuele Milan Italy
Department of Internal Medicine and Medical Specialties University of Genoa Genoa Italy
Department of Internal Medicine Hematology Oncology Ochsner Medical Center New Orleans LA
Department of Medical Oncology Army Hospital Research and Referral New Delhi India
Department of Medical Oncology Centre Hospitalier de Jolimont Belgium
Department of Medical Oncology Hospital Ramón y Cajal Madrid Spain
Department of Medical Oncology Maggiore della Carità University Hospital Novara Italy
Department of Medical Oncology MD Anderson Cancer Center Madrid Madrid Spain
Department of Oncology IRCCS Humanitas Research Hospital Rozzano Milan Italy
Department of Oncology San Camillo Forlanini Hospital Rome Italy
Department of Urology Medical University of Innsbruck Innsbruck Austria
Department of Urology University Hospital Bonn Bonn Germany
Dipartimento di Oncologia Medica Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy
Division of Medical Oncology A O U Consorziale Policlinico di Bari Bari Italy
Division of Medical Oncology National Cancer Centre Singapore Singapore
Division of Oncology Department of Internal Medicine Medical University of Graz Graz Austria
IRCCS Ospedale Policlinico San Martino Genoa Italy
Latin American Cooperative Oncology Group LACOG
Markey Cancer Center University of Kentucky Lexington KY
Medical Oncology 1 IRCCS Regina Elena National Cancer Institute Rome Italy
Medical Oncology Department La Paz University Hospital Madrid Spain
Medical Oncology IRCCS Azienda Ospedaliero Universitaria di Bologna Bologna Italia
Medical Oncology Tawam Hospital Al Ain United Arab Emirates
Medical Oncology Unit Santa Chiara Hospital Trento Italy
Oncologia Medica Fondazione Policlinico Universitario Agostino Gemelli IRCCS Roma Italy
Oncologia Medica Ospedale Maggiore di Cremona Italy
Oncology 3 Unit Department of Oncology Istituto Oncologico Veneto IOV IRCCS Padova Italy
Oncology and Hematology Department Hospital Santa Lucia Brasília Federal District Brazil
Oncology Candiolo Cancer Institute IRCCS FPO Torino Italy
Oncology Unit 2 University Hospital of Pisa Pisa Italy
Oncology Unit A R N A S Civico Palermo Italy
Oncology Unit Macerata Hospital Macerata Italy
Ospedale San Paolo Medical Oncology Savona Italy
Unità di Oncologia Medica Azienda Ospedaliero Universitaria di Cagliari Cagliari Italy
UOC di Oncologia Azienda Ospedaliera di Rilievo Nazionale Cardarelli di Napoli Naples Italy
UOC Oncologia Azienda Ospedaliera Ospedali Riuniti Marche Nord Italy
Urologic Oncology Champalimaud Clinical Center Lisbon Portugal
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24001186
- 003
- CZ-PrNML
- 005
- 20240213094423.0
- 007
- ta
- 008
- 240109s2023 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.clgc.2023.03.006 $2 doi
- 035 __
- $a (PubMed)37062658
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Santoni, Matteo $u Oncology Unit, Macerata Hospital, Macerata, Italy
- 245 10
- $a Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1) / $c M. Santoni, F. Massari, ZW. Myint, R. Iacovelli, M. Pichler, U. Basso, J. Kopecky, J. Kucharz, S. Buti, A. Salfi, T. Büttner, U. De Giorgi, R. Kanesvaran, O. Fiala, E. Grande, PA. Zucali, G. Fornarini, MT. Bourlon, S. Scagliarini, J. Molina-Cerrillo, G. Aurilio, MR. Matrana, R. Pichler, C. Cattrini, T. Büchler, E. Seront, F. Calabrò, A. Pinto, R. Berardi, A. Zgura, G. Mammone, J. Ansari, F. Atzori, R. Chiari, R. Zakopoulou, O. Caffo, G. Procopio, M. Bassanelli, I. Zampiva, C. Messina, Z. Küronya, A. Mosca, D. Bhuva, N. Vau, L. Incorvaia, SE. Rebuzzi, G. Roviello, IO. Zabalza, A. Rizzo, V. Mollica, I. Catalini, FSM. Monteiro, R. Montironi, N. Battelli, M. Rizzo, C. Porta
- 520 9_
- $a BACKGROUND: Obesity has been associated with improved response to immunotherapy in cancer patients. We investigated the role of body mass index (BMI) in patients from the ARON-1 study (NCT05287464) treated by dual immuno-oncology agents (IO+IO) or a combination of immuno-oncology drug and a tyrosine kinase inhibitors (TKI) as first-line therapy for metastatic renal cell carcinoma (mRCC). PATIENTS AND METHODS: Medical records of patients with documented mRCC treated by immuno-oncology combinations were reviewed at 47 institutions from 16 countries. Patients were assessed for overall survival (OS), progression-free survival (OS), and overall clinical benefit (OCB), defined as the sum of the rate of partial/complete responses and stable disease. Univariate and multivariate analyses were used to explore the association of variables of interest with survival. RESULTS: A total of 675 patients were included; BMI was >25 kg/m2 in 345 patients (51%) and was associated with improved OS (55.7 vs. 28.4 months, P < .001). The OCB of patients with BMI >25 kg/m2 versus those with BMI ≤25 kg/m2 was significantly higher only in patients with nonclear cell histology (81% vs. 65%, P = .011), and patients with liver metastases (76% vs. 58%, P = .007), Neutrophil to lymphocyte ratio >4 (77% vs 62%, P = .022) or treated by nivolumab plus ipilimumab (77% vs. 64%, P = .044). In the BMI ≤25 kg/m2 subgroup, significant differences were found between patients with NLR >4 versus ≤4 (62% vs. 82%, P = .002) and patients treated by IO+IO versus IO+TKIs combinations (64% vs. 83%, P = .002). CONCLUSION: Our study suggests that the prognostic significance and the association of BMI with treatment outcome varies across clinico-pathological mRCC subgroups.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a karcinom z renálních buněk $x patologie $7 D002292
- 650 12
- $a nádory ledvin $x patologie $7 D007680
- 650 _2
- $a index tělesné hmotnosti $7 D015992
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a inhibitory proteinkinas $x terapeutické užití $7 D047428
- 650 _2
- $a retrospektivní studie $7 D012189
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Massari, Francesco $u Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italia. Electronic address: fmassari79@gmail.com
- 700 1_
- $a Myint, Zin W $u Markey Cancer Center, University of Kentucky, Lexington, KY
- 700 1_
- $a Iacovelli, Roberto $u Oncologia Medica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy
- 700 1_
- $a Pichler, Martin $u Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
- 700 1_
- $a Basso, Umberto $u Oncology 3 Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy
- 700 1_
- $a Kopecky, Jindrich $u Department of Clinical Oncology and Radiotherapy, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
- 700 1_
- $a Kucharz, Jakub $u Department of Uro-oncology, Maria Sklodowska-Curie National Research Institute of Oncology Warsaw, Warsaw, Poland
- 700 1_
- $a Buti, Sebastiano $u Medical Oncology Unit, University Hospital of Parma - Department of Medicine and Surgery, University of Parma, Parma, Italy
- 700 1_
- $a Salfi, Alessia $u Oncology Unit 2, University Hospital of Pisa, Pisa, Italy
- 700 1_
- $a Büttner, Thomas $u Department of Urology, University Hospital Bonn (UKB), Bonn, Germany
- 700 1_
- $a De Giorgi, Ugo $u Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
- 700 1_
- $a Kanesvaran, Ravindran $u Division of Medical Oncology, National Cancer Centre Singapore, Singapore
- 700 1_
- $a Fiala, Ondřej $u Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic
- 700 1_
- $a Grande, Enrique $u Department of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain
- 700 1_
- $a Zucali, Paolo Andrea $u Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; Department of Oncology, IRCCS Humanitas Research Hospital, Rozzano - Milan, Italy
- 700 1_
- $a Fornarini, Giuseppe $u IRCCS Ospedale Policlinico San Martino, Genoa, Italy
- 700 1_
- $a Bourlon, Maria T $u Hematology and Oncology Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
- 700 1_
- $a Scagliarini, Sarah $u UOC di Oncologia, Azienda Ospedaliera di Rilievo Nazionale Cardarelli di Napoli, Naples, Italy
- 700 1_
- $a Molina-Cerrillo, Javier $u Department of Medical Oncology, Hospital Ramón y Cajal, Madrid, Spain
- 700 1_
- $a Aurilio, Gaetano $u Medical Oncology Division of Urogenital and Head and Neck Tumours, IEO, European Institute of Oncology IRCCS, Milan, Italy
- 700 1_
- $a Matrana, Marc R $u Department of Internal Medicine, Hematology/Oncology, Ochsner Medical Center, New Orleans, LA
- 700 1_
- $a Pichler, Renate $u Department of Urology, Medical University of Innsbruck, Innsbruck, Austria
- 700 1_
- $a Cattrini, Carlo $u Department of Medical Oncology, "Maggiore della Carità" University Hospital, Novara, Italy
- 700 1_
- $a Büchler, Tomas $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czech Republic
- 700 1_
- $a Seront, Emmanuel $u Department of Medical Oncology, Centre Hospitalier de Jolimont, Belgium
- 700 1_
- $a Calabrò, Fabio $u Department of Oncology, San Camillo Forlanini Hospital, Rome, Italy
- 700 1_
- $a Pinto, Alvaro $u Medical Oncology Department, La Paz University Hospital, Madrid, Spain
- 700 1_
- $a Berardi, Rossana $u Department of Medical Oncology, Università Politecnica delle Marche, AOU Ospedali Riuniti delle Marche, Ancona, Italy
- 700 1_
- $a Zgura, Anca $u Department of Oncology-Radiotherapy, Prof. Dr. Alexandru Trestioreanu Institute of Oncology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
- 700 1_
- $a Mammone, Giulia $u Department of Radiological, Oncological and Anatomo-Pathological Science, "Sapienza" University of Rome, Rome, Italy
- 700 1_
- $a Ansari, Jawaher $u Medical Oncology, Tawam Hospital, Al Ain, United Arab Emirates
- 700 1_
- $a Atzori, Francesco $u Unità di Oncologia Medica, Azienda Ospedaliero Universitaria di Cagliari, Cagliari, Italy
- 700 1_
- $a Chiari, Rita $u UOC Oncologia, Azienda Ospedaliera Ospedali Riuniti Marche Nord, Italy
- 700 1_
- $a Zakopoulou, Roubini $u 2nd Propaedeutic Dept of Internal Medicine, ATTIKON University Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
- 700 1_
- $a Caffo, Orazio $u Medical Oncology Unit, Santa Chiara Hospital, Trento, Italy
- 700 1_
- $a Procopio, Giuseppe $u Dipartimento di Oncologia Medica, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Oncologia Medica, Ospedale Maggiore di Cremona, Italy
- 700 1_
- $a Bassanelli, Maria $u Medical Oncology 1-IRCCS Regina Elena National Cancer Institute, Rome, Italy
- 700 1_
- $a Zampiva, Ilaria $u Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy
- 700 1_
- $a Messina, Carlo $u Oncology Unit, A.R.N.A.S. Civico, Palermo, Italy
- 700 1_
- $a Küronya, Zsófia $u Department of Genitourinary Medical Oncology and Clinical Pharmacology, National Institute of Oncology, Budapest, Hungary
- 700 1_
- $a Mosca, Alessandra $u Oncology, Candiolo Cancer Institute, IRCCS-FPO, Torino, Italy
- 700 1_
- $a Bhuva, Dipen $u Department of Medical Oncology, Army Hospital Research and Referral, New Delhi, India
- 700 1_
- $a Vau, Nuno $u Urologic Oncology, Champalimaud Clinical Center, Lisbon, Portugal
- 700 1_
- $a Incorvaia, Lorena $u Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy
- 700 1_
- $a Rebuzzi, Sara Elena $u Ospedale San Paolo, Medical Oncology, Savona, Italy; Department of Internal Medicine and Medical Specialties (Di.M.I.), University of Genoa, Genoa, Italy
- 700 1_
- $a Roviello, Giandomenico $u Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy
- 700 1_
- $a Zabalza, Ignacio Ortego $u Department of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain
- 700 1_
- $a Rizzo, Alessandro $u Struttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico "Don Tonino Bello", I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Bari, Italy
- 700 1_
- $a Mollica, Veronica $u Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italia
- 700 1_
- $a Catalini, Ilaria $u Oncology Unit, Macerata Hospital, Macerata, Italy
- 700 1_
- $a Monteiro, Fernando Sabino M $u Latin American Cooperative Oncology Group - LACOG; Oncology and Hematology Department, Hospital Santa Lucia, Brasília, Federal District, Brazil
- 700 1_
- $a Montironi, Rodolfo $u Molecular Medicine and Cell Therapy Foundation, Polytechnic University of the Marche Region, Ancona, Italy
- 700 1_
- $a Battelli, Nicola $u Oncology Unit, Macerata Hospital, Macerata, Italy
- 700 1_
- $a Rizzo, Mimma $u Division of Medical Oncology, A.O.U. Consorziale Policlinico di Bari, Bari, Italy
- 700 1_
- $a Porta, Camillo $u Division of Medical Oncology, A.O.U. Consorziale Policlinico di Bari, Bari, Italy; Chair of Oncology, Interdisciplinary Department of Medicine, University of Bari "Aldo Moro", Bari, Italy
- 773 0_
- $w MED00188741 $t Clinical genitourinary cancer $x 1938-0682 $g Roč. 21, č. 5 (2023), s. e309-e319.e1
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37062658 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240109 $b ABA008
- 991 __
- $a 20240213094420 $b ABA008
- 999 __
- $a ok $b bmc $g 2049658 $s 1210880
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 21 $c 5 $d e309-e319.e1 $e 20230320 $i 1938-0682 $m Clinical genitourinary cancer $n Clin Genitourin Cancer $x MED00188741
- LZP __
- $a Pubmed-20240109
